Combination of Irreversible Electroporation and STING Agonist for Effective Cancer Immunotherapy

• Main Authors: Eun-Jin Go, Hannah Yang, Hong Jae Chon, DaSom Yang, WonHyoung Ryu, Dong-Hyun Kim, Dong Keun Han, Chan Kim, Wooram Park
• Format: Article
• Language: English
• Published: MDPI AG 2020-10-01
• Series: Cancers
• Subjects: cancer immunotherapy; irreversible electroporation (IRE); stimulator of IFN genes (STING) agonists; immunogenic cell death (ICD); combinational treatment
• Online Access: https://www.mdpi.com/2072-6694/12/11/3123

Recently, cancer immunotherapy has received attention as a viable solution for the treatment of refractory tumors. However, it still has clinical limitations in its treatment efficacy due to inter-patient tumor heterogeneity and immunosuppressive tumor microenvironment (TME). In this study, we demonstrated the triggering of anti-cancer immune responses by a combination of irreversible electroporation (IRE) and a stimulator of interferon genes (STING) agonist. Optimal electrical conditions inducing damage-associated molecular patterns (DAMPs) by immunogenic cell death (ICD) were determined through in vitro 2D and 3D cell experiments. In the in vivo syngeneic lung cancer model, the combination of IRE and STING agonists demonstrated significant tumor growth inhibition. We believe that the combination strategy of IRE and STING agonists has potential for effective cancer immunotherapy.